Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821336 | 0.81 | CDC25A (0.33) | TSHRCDC25A | |
| SCHEMBL19821346 | 0.80 | CDC25A (0.38) | TSHRCDC25AMMP1MMP2TP53 | |
| SCHEMBL19821341 | 0.76 | CDC25A (0.41) | TSHRCDC25AMMP1MMP2TP53 | |
| SCHEMBL19821337 | 0.75 | CDC25A (0.43) | TSHRCDC25AMMP1MMP2TP53 | |
| Diethyl Hydrogen Phosphate SCHEMBL829439 | 0.74 | CDC25A (0.42) | TSHRCDC25AMMP1MMP2TP53 | |
| Diethyl Hydrogen Phosphate SCHEMBL830252 | 0.73 | CDC25A (0.44) | TSHRCDC25AMMP1MMP2TP53 | |
| Diethyl Hydrogen Phosphate SCHEMBL1788510 | 0.71 | TSHR (0.53) | TSHRCDC25ATP53TDP1 | |
| Diethyl Hydrogen Phosphate SCHEMBL11810821 | 0.71 | TSHR (0.53) | TSHRCDC25ATP53TDP1 | |
| Diethyl Hydrogen Phosphate SCHEMBL11123966 | 0.71 | TSHR (0.53) | TSHRCDC25ATP53TDP1 | |
| Diethyl Hydrogen Phosphate SCHEMBL10794081 | 0.71 | TSHR (0.53) | TSHRCDC25AMMP1MMP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240216288-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-04 | — | — | US | disclosed |
| US-20240207374-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING GLUCOSE-6-PHOSPHATASE AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20240207444-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PHENYLALANINE HYDROXYLASE AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20240024506-A1 | POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240016827-A1 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF FORMULATING THE SAME | MODERNATX, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11859215-B2 | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders | MODERNATX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | MODERNATX, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802146-B2 | Polynucleotides encoding anti-chikungunya virus antibodies | MODERNATX, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230277457-A1 | METHODS OF PREPARING LIPID NANOPARTICLES | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-07 | — | — | US | disclosed |
| US-11744801-B2 | Methods of making lipid nanoparticles | MODERNATX, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230257738-A1 | MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-08-17 | — | — | US | disclosed |
| US-20230235298-A1 | PHENYLALANINE HYDROXYLASE VARIANTS AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11649461-B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | MODERNATX, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257738-A1 | MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS | NSUN3, NSUN2, METTL16 | TSHR 1321/4885CDC25A 3933/4885MMP1 4420/4885 |
| US-20240016827-A1 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF FORMULATING THE SAME | LCAT, FASN, LIPC | TSHR 4671/4885CDC25A 3431/4885MMP1 4233/4885 |
| US-20240216288-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS AND USES THEREOF | PCCA, ACACA, PC | TSHR 3853/4885CDC25A 4108/4885MMP1 4678/4885 |
| US-20240207374-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING GLUCOSE-6-PHOSPHATASE AND USES THEREOF | G6PC1, GNPDA1, GPI | TSHR 4186/4885CDC25A 2053/4885MMP1 3174/4885 |
| US-11802146-B2 | Polynucleotides encoding anti-chikungunya virus antibodies | CHIA, EIF2AK2, POLRMT | TSHR 4704/4885CDC25A 3577/4885MMP1 4392/4885 |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | MMAB, NSUN3, MSH6 | TSHR 4464/4885CDC25A 4472/4885MMP1 3759/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | TSHR 2476/4885CDC25A 3971/4885MMP1 2497/4885 |
| US-20240207444-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PHENYLALANINE HYDROXYLASE AND USES THEREOF | PAH, SARNP, ABHD16A | TSHR 3703/4885CDC25A 4834/4885MMP1 4365/4885 |
| US-11744801-B2 | Methods of making lipid nanoparticles | PLTP, LNPEP, LNPK | TSHR 2343/4885CDC25A 2947/4885MMP1 4276/4885 |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | CFTR, SLC47A1, TMEM205 | TSHR 2476/4885CDC25A 3971/4885MMP1 2497/4885 |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | TSHR 2383/4885CDC25A 4651/4885MMP1 1300/4885 |
| US-20230235298-A1 | PHENYLALANINE HYDROXYLASE VARIANTS AND USES THEREOF | PAH, FARSA, P4HA1 | TSHR 3017/4885CDC25A 4858/4885MMP1 3392/4885 |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | GBA1, GAA, GLA | TSHR 3568/4885CDC25A 3408/4885MMP1 1039/4885 |
| US-11859215-B2 | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders | OTC, ODC1, OAT | TSHR 2931/4885CDC25A 2585/4885MMP1 3562/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | TSHR 3374/4885CDC25A 4271/4885MMP1 3454/4885 |
| US-20230277457-A1 | METHODS OF PREPARING LIPID NANOPARTICLES | PLTP, LIPA, CETP | TSHR 2460/4885CDC25A 2145/4885MMP1 4422/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | TSHR 3374/4885CDC25A 4271/4885MMP1 3454/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | TSHR 1695/4885CDC25A 2859/4885MMP1 4474/4885 |
| US-11649461-B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | GBA1, GAA, GLA | TSHR 3512/4885CDC25A 3534/4885MMP1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.